Literature DB >> 11353653

In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.

P C Fuchs1, A L Barry, S D Brown.   

Abstract

This study compared the in vitro activities of the new long-half-life carbapenem ertapenem (also known as MK-0826 and L-749,345) with those of imipenem, amoxicillin-clavulanate, and ciprofloxacin against 5,558 recent clinical isolates from 11 North American medical centers. We confirmed the greater activity of ertapenem than of imipenem against the Enterobacteriaceae and the greater activity of imipenem against pseudomonads and gram-positive bacteria.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11353653      PMCID： PMC90573          DOI： 10.1128/AAC.45.6.1915-1918.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

2.  In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.

Authors:  J Kohler; K L Dorso; K Young; G G Hammond; H Rosen; H Kropp; L L Silver
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Authors:  J G Sundelof; R Hajdu; C J Gill; R Thompson; H Rosen; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.

Authors:  G Jacoby; P Han; J Tran
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.

Authors:  I Odenholt; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).

Authors:  C J Gill; J J Jackson; L S Gerckens; B A Pelak; R K Thompson; J G Sundelof; H Kropp; H Rosen
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
  6 in total
  21 in total

1.  Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae.

Authors:  George A Jacoby; Debra M Mills; Nancy Chow
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  Multicenter antimicrobial susceptibility survey of gram-negative bacteria isolated from patients with community-acquired infections in the People's Republic of China.

Authors:  Thomas K W Ling; Jianhui Xiong; Yunsong Yu; Ching Ching Lee; Huifen Ye; Peter M Hawkey
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit.

Authors:  S V Yakovlev; L S Stratchounski; G L Woods; B Adeyi; K A McCarroll; J A Ginanni; I R Friedland; C A Wood; M J DiNubile
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-10       Impact factor: 3.267

4.  Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.

Authors:  Katie E Cardone; Darren W Grabe; Robert W Kulawy; Rachid Daoui; Joseph Roglieri; Shari Meola; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 5.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Ertapenem: a review of its use in the management of bacterial infections.

Authors:  Monique Curran; Dene Simpson; Caroline Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.

Authors:  Joseph S Solomkin; Albert E Yellin; Ori D Rotstein; Nicolas V Christou; E Patchen Dellinger; Jose M Tellado; Osvaldo Malafaia; Alvaro Fernandez; Kyuran A Choe; Alexandra Carides; Vilas Satishchandran; Hedy Teppler
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

8.  Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study.

Authors:  Kevin M Tomera; Emmanuel A Burdmann; Oscar G Pamo Reyna; Qi Jiang; Wendy M Wimmer; Gail L Woods; Richard M Gesser
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

9.  Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.

Authors:  Fausto de Lalla
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

10.  Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.

Authors:  Mao Mao An; Zui Zou; Hui Shen; Jun Dong Zhang; Meng Li Chen; Ping Liu; Rui Wang; Yuan Ying Jiang
Journal:  BMC Infect Dis       Date:  2009-12-02       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.